UPDATE: AT-005 Benefits In Combination With 2 SPecific Chemotherapy Protocols In 2 Randomized, Placebo-Controlled Studies

by Paul Quintaro, Benzinga Editor
September 24, 2015 6:04 PM | 5 seconds read |
AT-005 results so not seem to be adding significant progression free survival in canine T-Cell lymphoma
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: News
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!